Stephen Michael Kelsey Sells 4,302 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Stephen Michael Kelsey sold 4,302 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the completion of the sale, the insider owned 295,398 shares in the company, valued at approximately $29,386,193.04. This trade represents a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Revolution Medicines Trading Down 3.5%

NASDAQ:RVMD opened at $95.78 on Friday. The stock has a fifty day moving average price of $102.96 and a two-hundred day moving average price of $76.81. The stock has a market capitalization of $18.98 billion, a price-to-earnings ratio of -16.21 and a beta of 0.99. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.14 and a current ratio of 7.14. Revolution Medicines, Inc. has a 1 year low of $29.17 and a 1 year high of $124.49.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter in the prior year, the business earned ($1.12) earnings per share. As a group, sell-side analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Large institutional interest — several big funds (General Atlantic, Norges Bank, Avoro, UBS, Polar Capital) have taken or increased stakes recently, which signals strong institutional conviction and can provide buying support. MarketBeat Institutional/Insider Summary
• Positive Sentiment: Analyst tone is largely favorable — multiple upgrades/initiations and a consensus “Buy” bias underpin positive sentiment among investors and can stabilize demand. Analyst Coverage Summary
• Neutral Sentiment: Company profile and pipeline are long-term positives but carry standard biotech clinical/readout risk — lead programs include RMC‑4630 (SHP2), RMC‑6291 (KRAS G12C) and RMC‑6236 (pan‑RAS).
• Neutral Sentiment: Recent results (Feb. 25) showed a wider-than-expected quarterly loss (EPS -$1.86 vs. -$1.56 est.), a reminder of ongoing cash burn and negative EPS guidance for the year — a typical headwind for development-stage biotechs. Earnings Summary
• Negative Sentiment: Unusual options activity — investors bought 12,797 put contracts (a ~131% increase vs. average put volume of 5,546), a bearish flow that can amplify near‑term downside and volatility.
• Negative Sentiment: Cluster of insider sales on Mar. 17 — several senior insiders trimmed positions (Mark A. Goldsmith 12,871 shares; Margaret A. Horn 4,583; Stephen M. Kelsey 4,302; Jack Anders 2,753; Lin Wei 2,073; Xiaolin Wang 2,010). Multiple Form 4 filings were submitted to the SEC, which can be interpreted negatively by some investors even if sales are for diversification or routine reasons. SEC filings: Read More. · Read More. · Read More. · Read More. · Read More. · Read More.

Hedge Funds Weigh In On Revolution Medicines

Several hedge funds have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. raised its position in Revolution Medicines by 82.9% during the fourth quarter. Rockefeller Capital Management L.P. now owns 598 shares of the company’s stock worth $48,000 after acquiring an additional 271 shares during the last quarter. Avoro Capital Advisors LLC acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at approximately $172,840,000. Corient Private Wealth LLC acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at approximately $215,000. Flax Pond Capital LLC purchased a new position in shares of Revolution Medicines during the 4th quarter worth approximately $632,000. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Revolution Medicines during the 4th quarter worth approximately $5,241,000. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RVMD. UBS Group began coverage on shares of Revolution Medicines in a report on Friday, February 27th. They set a “buy” rating on the stock. Jefferies Financial Group started coverage on shares of Revolution Medicines in a report on Monday, March 16th. They issued a “buy” rating for the company. Evercore raised Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, February 25th. Benchmark restated an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research note on Friday, January 9th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.